Paloma Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Paloma Partners’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,029	Closed	-$13.4K	–	1438
2024 Q2	$13.4K	Buy	+1,029	New	+$17K	﹤0.01%	1203
2020 Q2	–	Sell	-712	Closed	-$205K	–	2158
2020 Q1	$205K	Buy	+712	New	+$196K	0.01%	887
2018 Q4	–	Sell	-1,484	Closed	-$379K	–	1537
2018 Q3	$379K	Buy	+1,484	New	+$410K	0.01%	1139
2016 Q3	–	Sell	-781	Closed	-$79K	–	1995
2016 Q2	$79K	Buy	+781	New	+$101K	﹤0.01%	2089

Other funds holding KPTI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Paloma Partners's KPTI Position: Q3 2024 in Review

Paloma Partners sold out of Karyopharm Therapeutics (KPTI) in Q3 2024, closing a stake of 1,029 shares — an estimated $13.4K sold.

Paloma Partners first reported a position in KPTI in Q2 2016 and held it in 4 quarters. The position peaked at $379K in Q3 2018. 91 funds tracked by Wall St. Rank hold KPTI as of Q3 2024.

Paloma Partners reported no remaining Karyopharm Therapeutics position as of Q3 2024 after selling out during the quarter.
Paloma Partners sold 1,029 Karyopharm Therapeutics shares in Q3 2024, an estimated $13.4K.
Paloma Partners first reported a position in Karyopharm Therapeutics in Q2 2016 and held it in 4 quarters.
Paloma Partners's Karyopharm Therapeutics position peaked at $379K in Q3 2018.
91 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.